JPWO2020047414A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020047414A5 JPWO2020047414A5 JP2021510846A JP2021510846A JPWO2020047414A5 JP WO2020047414 A5 JPWO2020047414 A5 JP WO2020047414A5 JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021510846 A JP2021510846 A JP 2021510846A JP WO2020047414 A5 JPWO2020047414 A5 JP WO2020047414A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- ripk2
- inhibitor
- immune cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 21
- 230000002401 inhibitory effect Effects 0.000 claims 21
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 16
- 210000003169 Central Nervous System Anatomy 0.000 claims 14
- 210000002865 immune cell Anatomy 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 102100014279 RIPK1 Human genes 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims 5
- 206010061536 Parkinson's disease Diseases 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 4
- 210000001130 Astrocytes Anatomy 0.000 claims 4
- 102100020401 NOD2 Human genes 0.000 claims 4
- 101700040223 NOD2 Proteins 0.000 claims 4
- 102000003802 alpha-Synuclein Human genes 0.000 claims 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims 4
- 230000002757 inflammatory Effects 0.000 claims 4
- 230000002887 neurotoxic Effects 0.000 claims 4
- 231100000189 neurotoxic Toxicity 0.000 claims 4
- 108010040003 polyglutamine Proteins 0.000 claims 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 3
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 3
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 3
- 210000000274 Microglia Anatomy 0.000 claims 3
- 108091000081 Phosphotransferases Proteins 0.000 claims 3
- 102000001253 Protein Kinases Human genes 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 3
- 210000003008 brain-resident macrophage Anatomy 0.000 claims 3
- 230000001419 dependent Effects 0.000 claims 3
- 230000002025 microglial Effects 0.000 claims 3
- 208000001183 Brain Injury Diseases 0.000 claims 2
- -1 C1q Proteins 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 2
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 208000008675 Hereditary Spastic Paraplegia Diseases 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 2
- 208000001089 Multiple System Atrophy Diseases 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 201000001203 Wilson disease Diseases 0.000 claims 2
- 201000006474 brain ischemia Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLOGLWKOHPIJLV-UHFFFAOYSA-N 6-tert-butylsulfonyl-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine Chemical compound C1=C(F)C=C2C(NC3=CC=NC4=CC=C(C=C43)S(=O)(=O)C(C)(C)C)=NNC2=C1 XLOGLWKOHPIJLV-UHFFFAOYSA-N 0.000 claims 1
- 102100019961 ATP7B Human genes 0.000 claims 1
- 101700032974 ATP7B Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 101700072041 CXCL1 Proteins 0.000 claims 1
- 210000003703 Cisterna Magna Anatomy 0.000 claims 1
- 210000001503 Joints Anatomy 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 201000001964 Menkes disease Diseases 0.000 claims 1
- LEBSTCDZKUSVOY-UHFFFAOYSA-N N-[2-[4-amino-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-2-methylpropyl]pyridine-4-carboxamide Chemical compound C1=CC(C)=CC=C1C1=NN(C(C)(C)CNC(=O)C=2C=CN=CC=2)C2=NC=NC(N)=C12 LEBSTCDZKUSVOY-UHFFFAOYSA-N 0.000 claims 1
- 102100020402 NOD1 Human genes 0.000 claims 1
- 101700059839 NOD1 Proteins 0.000 claims 1
- 101700049309 NOS2 Proteins 0.000 claims 1
- 102100002496 NOS2 Human genes 0.000 claims 1
- 210000003928 Nasal Cavity Anatomy 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- 101700069676 RIPK1 Proteins 0.000 claims 1
- 102100014268 RIPK3 Human genes 0.000 claims 1
- 101700064990 RIPK3 Proteins 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 210000002330 Subarachnoid Space Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725647P | 2018-08-31 | 2018-08-31 | |
| US62/725,647 | 2018-08-31 | ||
| PCT/US2019/049071 WO2020047414A1 (fr) | 2018-08-31 | 2019-08-30 | Inhibition de kinases ripk pour traiter des maladies neurodégénératives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535152A JP2021535152A (ja) | 2021-12-16 |
| JPWO2020047414A5 true JPWO2020047414A5 (fr) | 2022-09-02 |
Family
ID=69643080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510846A Pending JP2021535152A (ja) | 2018-08-31 | 2019-08-30 | 神経変性障害を処置するためのｒｉｐキナーゼの阻害法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210322427A1 (fr) |
| EP (1) | EP3843773A4 (fr) |
| JP (1) | JP2021535152A (fr) |
| KR (1) | KR20210053303A (fr) |
| CN (1) | CN112638405A (fr) |
| AU (1) | AU2019328532A1 (fr) |
| CA (1) | CA3109364A1 (fr) |
| WO (1) | WO2020047414A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023055733A1 (fr) * | 2021-09-30 | 2023-04-06 | The Scripps Research Institute | Composés pour réduire la neuro-inflammation |
| WO2023229445A1 (fr) * | 2022-05-27 | 2023-11-30 | 주식회사 진큐어 | Nouveau peptide et son utilisation |
| WO2024099363A1 (fr) * | 2022-11-09 | 2024-05-16 | 宁波康柏睿格医药科技有限公司 | Composition pharmaceutique d'inhibiteur de rip2 en combinaison avec un inhibiteur de point de contrôle immunitaire et son utilisation |
| CN116617224A (zh) * | 2023-05-04 | 2023-08-22 | 上海交通大学医学院附属瑞金医院 | OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011112588A2 (fr) * | 2010-03-08 | 2011-09-15 | Case Western Reserve University | Compositions et méthodes pour le traitement de troubles inflammatoires |
| US20120046329A1 (en) * | 2010-08-10 | 2012-02-23 | Sanford-Burnham Medical Research Institute | Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof |
| EP2620156B1 (fr) * | 2010-08-23 | 2019-03-27 | Kang Stem Biotech Co., Ltd. | Composition pharmaceutique utilisée dans la prophylaxie ou le traitement de maladies immunitaires ou inflammatoires, contenant des cellules souches traitées par agoniste du nod2 ou un de leurs produits mis en culture |
| LT2729173T (lt) * | 2011-07-06 | 2016-10-10 | Sykehuset Sorlandet Hf | Egfr taikinių terapija |
| WO2014066894A1 (fr) * | 2012-10-26 | 2014-05-01 | Case Western Reserve University | Biomarqueurs pour une application liée à l'activité de nod2 et/ou rip2 |
| US20170003280A1 (en) * | 2014-01-11 | 2017-01-05 | The J. David Gladstone Institutes | In vitro assays for inhibition of microglial activation |
| WO2016096709A1 (fr) * | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Dérivés hétérocycliques modulant l'activité de certaines protéines kinases |
| KR20160129609A (ko) * | 2015-04-30 | 2016-11-09 | 삼성전자주식회사 | Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도 |
-
2019
- 2019-08-30 EP EP19853529.6A patent/EP3843773A4/fr active Pending
- 2019-08-30 KR KR1020217008526A patent/KR20210053303A/ko active Search and Examination
- 2019-08-30 US US17/271,966 patent/US20210322427A1/en not_active Abandoned
- 2019-08-30 CN CN201980057467.0A patent/CN112638405A/zh active Pending
- 2019-08-30 WO PCT/US2019/049071 patent/WO2020047414A1/fr unknown
- 2019-08-30 CA CA3109364A patent/CA3109364A1/fr active Pending
- 2019-08-30 JP JP2021510846A patent/JP2021535152A/ja active Pending
- 2019-08-30 AU AU2019328532A patent/AU2019328532A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10478442B2 (en) | Method for the treatment of Dravet Syndrome | |
| Moss et al. | Safety and efficacy of flecainide in subjects with long QT‐3 syndrome (ΔKPQ mutation): a randomized, double‐blind, placebo‐controlled clinical trial | |
| JP2014517050A5 (fr) | ||
| WO2009017453A1 (fr) | Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958 | |
| NZ601547A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| US11439624B2 (en) | Promoting sleep using AT1 receptor blockers | |
| JP2011504474A5 (fr) | ||
| JPWO2020047414A5 (fr) | ||
| US20130324572A1 (en) | Remedy for psychoneurotic diseases | |
| Ortega et al. | Indications of dexmedetomidine in the current sedoanalgesia trends in the critical patient | |
| US6855735B2 (en) | Ketamine treatment of restless legs syndrome | |
| US20220168318A1 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
| TWI841027B (zh) | 手部溼疹之治療 | |
| JP2013536206A5 (fr) | ||
| US9125911B2 (en) | Combined systemic and topical treatment of disordered tissues | |
| JP2017513845A5 (fr) | ||
| JP2020526575A5 (fr) | ||
| KR102693607B1 (ko) | 하지 불안 증후군을 치료하기 위한 치료제 | |
| Monti et al. | Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics | |
| JP6734469B2 (ja) | ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ | |
| JPWO2021211489A5 (fr) | ||
| KR20220066985A (ko) | 퇴행성 신경질환의 치료 방법 | |
| Kelley et al. | Hyperkinetic movement disorders caused by corpus striatum infarcts: brain MRI/CT findings in three cases | |
| JPWO2019211081A5 (fr) | ||
| Di Fabio et al. | Hydroxyzine hydrochloride in familial restless legs syndrome |